ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma, Systemic"

  • Abstract Number: 2366 • ACR Convergence 2023

    Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma

    Hung Vo1, Aarohi Mehendale2, Anahita Pilvar3, Eugene Kissin4, Marcin Trojanowski5, Michael York6, Darren Roblyer2 and Andreea Bujor6, 1Boston Medical Center, Peabody, MA, 2Department of Biomedical Engineering, Boston University, Boston, MA, 3Department of Electrical and Computer Engineering, Boston University, Boston, MA, 4Boston University, Newton, MA, 5Boston University School of Medicine, Boston, MA, 6Boston University, Boston, MA

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by excessive collagen deposition in the skin and internal organs, along with vascular dysfunction. The modified…
  • Abstract Number: 0332 • ACR Convergence 2023

    Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis

    Jeong Min Yu1, John VanBuren2, Angela Child2, Jessica Alvey2, Lisa Mandl3, Laura Pinheiro4, Shervin Assassi5, Elana Bernstein6, Flavia Castelino7, Lorinda Chung8, Luke Evnin9, Tracy Frech10, Faye Hant11, Laura Hummers12, Dinesh Khanna13, Kimberly Lakin1, Dorota Lebiedz-Odrobina14, Yiming Luo15, Ashima Makol16, Jerry Molitor17, Duncan Moore18, Carrie Richardson19, Nora Sandorfi20, Ami Shah21, Ankoor Shah22, Victoria Shanmugam23, Brian Skaug24, Virginia Steen25, Elizabeth Volkmann26 and Jessica Gordon1, 1Hospital for Special Surgery, New York, NY, 2University of Utah, Salt Lake City, UT, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Weill Cornell Medicine College, New York, NY, 5University of Texas McGovern Medical School at Houston, Houston, TX, 6Columbia University, New York, NY, 7Massachusetts General Hospital, Boston, MA, 8Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 9Scleroderma Research Foundation, Brisbane, CA, 10Vanderbilt University Medical Center, Nashville, TN, 11Medical University of South Carolina, Charleston, SC, 12Johns Hopkins University, Baltimore, MD, 13University of Michigan, Ann Arbor, MI, 14University of Utah, Cottonwood Heights, UT, 15Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 16Mayo Clinic, Rochester, MN, Rochester, MN, 17University of Minnesota, Minneapolis, MN, 18Northwestern Memorial Hospital, Chicago, IL, 19Northwestern University, Riverside, IL, 20University of Pennsylvania, Philadelphia, PA, 21Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 22Duke University, Durham, NC, 23Victoria Shanmugam, MD, Great Falls, VA, 24Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 25Georgetown University School of Medicine, Washington, DC, 26University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Skin disease is a hallmark of systemic sclerosis (SSc). The modified Rodnan skin score (mRSS) is physician performed measurement that assesses the extent and…
  • Abstract Number: 1142 • ACR Convergence 2023

    A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease

    Nikita Jhawar, Claire Wilson, Andy Abril, Li Zhuo and Yaohua Ma, Mayo Clinic, Jacksonville, FL

    Background/Purpose: Connective tissue diseases such as scleroderma are frequently associated with interstitial lung disease (ILD). Detection of autoantibodies is crucial in characterizing disease phenotypes, but…
  • Abstract Number: 2595 • ACR Convergence 2023

    A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)

    Shefali Khanna Sharma1, Jithin Mathew1, Chirag Kopp1, Varun Dhir2, Sahajal Dhooria3, Anindita Sinha1 and Sanjay Jain1, 1Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER, CHD, INDIA, Chandigarh, India, 3PGI CHANDIGARH, Chandigarh, India

    Background/Purpose: Interstitial lung disease in systemic sclerosis(SSc-ILD) is heterogeneous with limited therapeutic options. Mycophenolate mofetil (MMF) is the most commonly used first line agent for…
  • Abstract Number: 0611 • ACR Convergence 2023

    Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis

    Jenice Cheah1, Jamie Perin2, Michael Hughes3, Julie Paik4, Christopher Mecoli2, Laura Hummers4, Ami Shah5, Fred Wigley6 and Zsuzsanna McMahan7, 1University of California Los Angeles, Los Angeles, CA, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, 4Johns Hopkins University, Baltimore, MD, 5Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 6Department of Rheumatology, Johns Hopkins Medicine, Baltimore, MD, 7Johns Hopkins Rheumatology, Lutherville, MD

    Background/Purpose: The gastrointestinal (GI) tract is the second most commonly affected organ in patients with systemic sclerosis (SSc). It is estimated that the small bowel…
  • Abstract Number: 1516 • ACR Convergence 2023

    Systemic Sclerosis Gastrointestinal Tract Vascular Biomarkers of Symptomatic Disease Activity

    Venkateswara Gogulamudi1, Sarah Wood2, Elizabeth Johnson2, Aaron Petrey3, Anthony Donato4 and Tracy Frech2, 1Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, 2Vanderbilt University Medical Center, Nashville, TN, 3University of Utah, Salt Lake City, UT, 4University of Utah and Salt Lake VAMC, Salt Lake City, UT

    Background/Purpose: Gastrointestinal tract symptoms are common in systemic sclerosis (SSc). The Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract Questionnaire (GIT 2.0)…
  • Abstract Number: 0612 • ACR Convergence 2023

    COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study

    Kimberly Lakin1, Jessica Gordon1, Yin Wu2, Linda Kwakkenbos3, Marie-Eve Carrier2, Richard Henry2, Christopher Denton4, Luc Mouthon5, Robert Spiera6 and Brett Thombs2, 1Hospital for Special Surgery, New York, NY, 2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, 3Radboud University, Nijmegen, Netherlands, 4University College London, London, United Kingdom, 5Hopital Cochin - Paris University, Paris, France, 6Hosptial for Special Surgery, New York, NY

    Background/Purpose: We previously surveyed individuals with systemic sclerosis (SSc) enrolled in Scleroderma Patient-centered Intervention Network (SPIN) Cohort between April-May 2021 to determine COVID-19 vaccination rates,…
  • Abstract Number: 1521 • ACR Convergence 2023

    Microvascular Remodeling After Autologous Stem Cell Transplant for Systemic Sclerosis

    Lisa Balistreri1, Megan Sullivan1, Florentina Berianu1, Ernesto Ayala2 and Andy Abril2, 1Mayo Clinic Florida, Jacksonville, FL, 2Mayo Clinic, Jacksonville, FL

    Background/Purpose: Autologous hematopoietic stem cell therapy (HSCT) is an effective therapy for patients with rapidly progressive systemic sclerosis (SSc) refractory to standard therapies. The disease…
  • Abstract Number: 0614 • ACR Convergence 2023

    Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis

    Liza Morales1, Robert Spiera2, Jessica Gordon1, Deanna Jannat-Khah1 and Kimberly Lakin1, 1Hospital for Special Surgery, New York, NY, 2Hosptial for Special Surgery, New York, NY

    Background/Purpose: Few studies have investigated the prevalence and risk factors of sexual dysfunction among individuals with systemic sclerosis (SSc). The purpose of this study is…
  • Abstract Number: 1523 • ACR Convergence 2023

    The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis

    Muruganandam Maheswari, Eyerusalem Akpan, Matthew Mcelwee, Meredith Keller, Angie Ariza - Hutchinson, Rosemina Patel, Wilmer Sibbitt, Frank O'Sullivan, Sharon nunez, N. Suzanne Emil and Roderick Fields, University of New Mexico, Albuquerque, NM

    Background/Purpose: Scleroderma renal crisis (SRC) is a rare but a life-threatening complication of systemic sclerosis (SSc), affecting 2-15% of patients with SSc. SRC has been…
  • Abstract Number: 0628 • ACR Convergence 2023

    Interstitial Lung Disease in Very Early Systemic Sclerosis

    Sinziana Muraru1, Carina Mihai1, Anna-Maria Hoffmann-Vold2, Cosimo Bruni1, Muriel Elhai3, Mike Becker4, Suzana Jordan1, Alexandru Garaiman1, Oliver Distler1 and Rucsandra Dobrota1, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Oslo University Hospital, Oslo, Norway, 3Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Interstitial lung disease (ILD) affects around 50% of patients with systemic sclerosis (SSc) and is the main cause of mortality. Preliminary data from small…
  • Abstract Number: 1526 • ACR Convergence 2023

    Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study

    Lisa Kaly1, mark Volevich1, shiri keret2, Abid Awisat3, Aniela Shouval1, Itzhak Rosner4, Michel Rozenbaum1, Nina Boulman1 and Doron Rimar1, 1Bnai Zion Medical Center, Haifa, Israel, 2Bnai Zion, Atlit, Israel, 3Bney-Zion Medical Center, Baqa Elgharbiya, Israel, 4Bnai Zion Medical Center/Technion, Haifa, Israel

    Background/Purpose: B cell depleting therapy (rituximab) and Autologous Hematopoietic Stem Cell transplantation (AHSCT) result in impaired ability to mount a humoral immune response. Evusheld (tixagevimab…
  • Abstract Number: 0630 • ACR Convergence 2023

    Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry

    Marissa Savoie1, Monica Harding2, Jessica Alvey2, John VanBuren2, Shervin Assassi3, Elana Bernstein4, Lorinda Chung5, Luke Evnin6, Tracy Frech7, Jessica Gordon8, Faye Hant9, Laura Hummers10, Dinesh Khanna11, Kimberly Lakin8, Dorota Lebiedz-Odrobina12, Yiming Luo13, Ashima Makol14, Jerry Molitor15, Duncan Moore16, Carrie Richardson17, Nora Sandorfi18, Ami Shah19, Ankoor Shah20, Brian Skaug21, Virginia Steen22, Elizabeth Volkmann23 and Flavia Castelino1, 1Massachusetts General Hospital, Boston, MA, 2University of Utah, Salt Lake City, UT, 3University of Texas McGovern Medical School at Houston, Houston, TX, 4Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, 5Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, 6Scleroderma Research Foundation, Brisbane, CA, 7Vanderbilt University Medical Center, Nashville, TN, 8Hospital for Special Surgery, New York, NY, 9Medical University of South Carolina, Charleston, SC, 10Johns Hopkins University, Baltimore, MD, 11University of Michigan, Ann Arbor, MI, 12University of Utah, Cottonwood Heights, UT, 13Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, 14Mayo Clinic, Rochester, MN, Rochester, MN, 15University of Minnesota, Minneapolis, MN, 16Northwestern University, Department of Rheumatology, Chicago, IL, 17Northwestern University, Chicago, IL, 18University of Pennsylvania, Philadelphia, PA, 19Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, 20Duke University, Durham, NC, 21Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 22Georgetown University School of Medicine, Washington, DC, 23University of California Los Angeles, Los Angeles, CA

    Background/Purpose: Digital ischemic ulcers (DIU) develop in 36-44% of patients with systemic sclerosis (SSc).1,2Prior international observational studies have evaluated characteristics of digital pitting and ulcers…
  • Abstract Number: 1528 • ACR Convergence 2023

    Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients

    Francesco Bonomi1, Arianna Damiani1, Carmela Coccia1, Juela Levani1, elisa Fiorentini2, silvia peretti1, Gemma Lepri1, martina orlandi1, francesca bartoli1, marco Matucci Cerinic3, silvia bellando randone1 and serena guiducci1, 1Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy, 2Department of Experimental and Clinical medicine, Division of Rheumatology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Firenze, Italy, 3Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy

    Background/Purpose: Treatment of systemic sclerosis (SSc) is challenging, and in the last 2 decades there has been an increasing interest for immunoglobulin (Igs) treatment as…
  • Abstract Number: 0635 • ACR Convergence 2023

    Clinical Characteristics and Longitudinal Outcomes of Patients with Childhood-Onset Systemic Sclerosis at a Tertiary Center

    Jessica Nguyen1, Andrea Ramirez2, Maria Pereira2, Eyal Muscal3, Manuel Silva-Carmona2 and Marietta De Guzman2, 1Baylor College of Medicine, Manvel, TX, 2Baylor College of Medicine, Houston, TX, 3Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX

    Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare autoimmune multisystemic condition with immune, fibrotic, and vascular manifestations. Although progress has been made in recognizing this…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology